Supplement Safety Critic Cohen Suggests Stronger, Responsive AER System
This article was originally published in The Tan Sheet
Executive Summary
Pieter Cohen says a “small fraction of what’s going on” with supplement-related adverse events is reported to MedWatch because many physicians as well as consumers are not aware they can report AEs to FDA. He also is critical of FDA and manufacturers’ responsiveness to reports submitted to MedWatch.
You may also be interested in...
DMAA Warnings Shed Light On FDA NDI Enforcement
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
Proposed OTC Switch Rule Anticipates Digital World
FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.
Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions
From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.